Fig. 4
From: Identification and evaluation of Pharmacological enhancers of the factor VII p.Q160R variant
Dose-response effect of abexinostat and tyloxapol on FVII-p.Q160R activity in plasma from FVII deficient patients. Citrated plasma was collected from 7 different FVII deficient patients harboring the p.Q160R variant. Dose-response analysis (range 0.1–10 µM) of abexinostat (A) and tyloxapol (B) on FVII activity was performed. Pooled normal plasma was used as a positive control. One representative patient is shown. EC50 (C) and Change of magnitude (D) of FVII activity in plasma samples from patients carrying the FVII-p.Q160R mutation stimulated with 10 µM abexinostat (n = 6) or tyloxapol (n = 7). Mean levels (+ SEM) are shown.
